NCT04324918View on ClinicalTrials.gov

Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis

PHASE3CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

October 23, 2018

Primary Completion Date

June 24, 2019

Study Completion Date

June 24, 2019

Conditions
Perennial Allergic Rhinitis
Interventions
DRUG

HCP1102

The participants will receive tretment of HCP1102(combination of Montelukast + Levocetrizine), orally, once daily for 4weeks.

DRUG

HGP1408

The participants will receive tretment of HGP1408(Levocetrizine), orally, once daily for 4weeks.

Trial Locations (1)

Unknown

Gangnam Severance Hospital., Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT04324918 - Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis | Biotech Hunter | Biotech Hunter